

**Table S2. Predicted individual TFV-DP elimination kinetics.**

Pat.#	$C_0(i)$ (fMol/ $10^6$ cells)	$k_{\text{out}}(i)$ ( $\text{h}^{-1}$ )	$t_{1/2}^b$ (h)
1	80.02	0.0054	129.2
2	91.21	0.0018	386.2
3	241	0.026	26.7
4	144.1	0.0023	296.9
5	61.33	0.0035	196.5
6	111.5	0.0064	109.1
7	338.6	0.023	29.7
8	75.61	0.0068	101.4
mean ( $\pm$ std)	143 ( $\pm$ 98)	0.0094 ( $\pm$ 0.0096)	159.4 ( $\pm$ 127)
weighted mean ( $\pm$ std)*	156 ( $\pm$ 166)	0.012 ( $\pm$ 0.01)	125.5 ( $\pm$ 134)
median (range)	101 (61;339)	0.0059 (0.002;0.026)	119.1 (26.7;386.2)

Estimated individual plateau concentrations  $C_0(i)$  and elimination rates  $k_{\text{out}}(i)$  of TFV-DP from PBMCs (after treatment cessation). Parameters were estimated assuming first-order decay kinetics according to:  $C_{\text{cell}}(i, t) = C_0(i) \cdot e^{-t \cdot k_{\text{out}}(i)}$  using the data from [1]. \* weighted mean =  $\frac{1}{\sum_i R^2(i)} \cdot \sum_i R^2(i) \cdot x(i)$ , where  $x(i)$  is either  $C_0(i)$ ,  $k_{\text{out}}(i)$  or  $t_{1/2}(i)$  and  $R^2(i)$  is the pearson's correlation coefficient between experimental and predicted decay. <sup>b</sup> Halflife computed using  $t_{1/2} = \ln(2)/k_{\text{out}}(i)$ .

## References

1. Hawkins T, Veikley W, Claire RLS, Guyer B, Clark N, et al. (2005) Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr 39: 406–411.